Esther Drill, DrPH

Principal Biostatistician
Epidemiology & Biostatistics
Directory
Epidemiology
Biostatistics
Health Outcomes
Computational Oncology
Administrative Resources
Career Opportunities
Educational Opportunities
Departmental Newsletter

Esther Drill, DrPH

Principal Biostatistician
Share
Share
Esther Drill

Email

[email protected]

Education

Columbia University

Current Research Interest 

Dr. Drill’s area of expertise lies in using statistical and computational approaches to applied research in cancer genomics. She has considerable experience with analyses of data from targeted sequencing platforms (including MSK IMPACT and HEME-PACT), as well as individual genome-wide platforms, such as RNA-Seq, gene expression arrays, and methylation assays. In addition, she has particular experience with integrative genomic analysis incorporating multiple genomic platforms, including large data sets from The Cancer Genome Atlas. She also collaborates with Lymphoma department physicians on clinical trial and observational study design and analysis.

Publications

Selected peer-reviewed publications:

  1. Mukherjee S, Bandlamudi C, Hellmann MD, Kemel Y, Drill E, Rizvi H, Tkachuk K, Khurram A, Walsh MF, Zauderer MG, Mandelker D, Topka S, Zehir A, Srinivasan P, Esai Selvan M, Carlo MI, Cadoo KA, Latham A, Hamilton JG, Liu YL, Lipkin SM, Belhadj S, Bond GL, Gümüş ZH, Klein RJ, Ladanyi M, Solit DB, Robson ME, Jones DR, Kris MG, Vijai J, Stadler ZK, Amos CI, Taylor BS, Berger MF, Rudin CM, Offit K. Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer. Cancer Epidemiol Biomarkers Prev. 2022 Apr 27:cebp. EPI-21-1287-A.2021.
  2. Lin RJ, Owens CN, Drill E, Iannotta A, Oliveros M, Schick DL, Noy A, Gerecitano JF, Drullinsky PR, Caron PC, Kumar A, Matasar MJ, Moskowitz C, Korc-Grodzicki B, Zelenetz AD, Salles GA, Hamlin PA. Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma. Haematologica. 2022 May 1;107(5):1144-1152.
  3. Boerner T, Drill E, Pak LM, Nguyen B, Sigel CS, Doussot A, Shin P, Goldman DA, Gonen M, Allen PJ, Balachandran VP, Cercek A, Harding J, Solit DB, Schultz N, Kundra R, Walch H, D’Angelica MI, DeMatteo RP, Drebin J, Kemeny NE, Kingham TP, Simpson AL, Hechtman JF, Vakiani E, Lowery MA, Ijzermans JNM, Buettner S, Koerkamp BG, Doukas M, Chandwani R, Jarnagin WR. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. Hepatology. 2021 Sep;74(3):1429-1444.
  4. Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, Rosen N, Iasonos A, Abdel-Wahab O, Hyman DM. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 March 13; 567; 521-524.
  5. Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E*, Shen R, Taylor AM, Cherniack AD, Thorsson V, Akbani R, Bowlby R, Wong CK, Wiznerowicz M, Sanchez-Vega F, Robertson AG, Schneider BG, Lawrence MS, Noushmehr H, Malta TM; Cancer Genome Atlas Network, Stuart JM, Benz CC, Laird PW. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell. 2018 Apr 5; 173(2): 291-304.